Publications by authors named "Roberto Antonio Pazo-Cid"
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Lancet Oncol
July 2024
Article Synopsis
- Current treatments for metastatic pancreatic ductal adenocarcinoma yield very low survival rates, prompting research into new therapies like mitazalimab combined with a modified chemotherapy regimen called mFOLFIRINOX.
- The OPTIMIZE-1 study enrolled 70 patients across 14 hospitals in Belgium, France, and Spain to evaluate the safety and effectiveness of this combination therapy, focusing on determining the optimal dose of mitazalimab as well as measuring tumor response.
- The trial successfully determined 900 μg/kg of mitazalimab as the recommended dose for the next phase and gathered data on the initial outcomes for the patients treated within the study timeframe from September 2021 to March 2023.
Background: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.
Methods: Retrospective, multicenter study including patients with metastatic pancreatic cancer, who started first-line treatment with nab-paclitaxel plus gemcitabine between December 2013 and June 2015 according to routine clinical practice.
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasm of the gastrointestinal tract. Rectum localisation is infrequent for these neoplasms, accounting for about 5% of all cases. Distant metastases of GIST are also rare.
View Article and Find Full Text PDF